OSS, The Netherlands, October 30 /PRNewswire/ -- Organon, the human healthcare business unit of Akzo Nobel, today announced that it has signed an exclusive, worldwide license agreement with Endotis Pharma concerning the development and commercialization of several antithrombotic compounds. Endotis is a specialty pharma company dedicated to the discovery and development of small-glyco drugs for applications in thrombosis and oncology.
Under the terms of the agreement, Endotis has acquired exclusive rights to develop and commercialize Org 42675, Org 217609 (a neutralizable follow-up of Org 42675) and Org 224283, three antithrombotic compounds with an innovative dual mechanism of action. Financial details are not disclosed.
Org 42675 and Org 217609 display a new and original dual mechanism of action, combining blood coagulation factor Xa inhibition and thrombin inhibition. Org 42675 has successfully completed two phase I clinical trials. Org 224283 also displays an innovative dual mechanism of action, combining factor Xa inhibition and an antiplatelet effect, both effects being neutralizable by a specific antidote. Org 224283 is at a preclinical-stage of development.
Charles Woler, Chairman and CEO of Endotis Pharma, declared: "We are delighted to sign this licensing agreement, as these compounds will strongly reinforce our position in thrombosis. Due to their oligosaccharide structure, they perfectly fit with our focus on small-glyco drugs. We are proud that Organon has faith in Endotis to develop these very promising compounds."
David Nicholson, executive vice president Research and Development of Organon added: "We are excited to bring this opportunity to Endotis. Organon will continue to be involved bringing in our expertise in manufacturing and development. This deal maximizes the chances of bringing these innovative compounds to patients in need of anti-thrombotic care."
About Organon Organon creates, manufactures and markets
|SOURCE N.V. Organon|
Copyright©2007 PR Newswire.
All rights reserved